Explore

Yale University Researchers Identify Drugs and Lifestyle Factors Linked to Altered Biological Aging Markers

Yale University Researchers Identify Drugs and Lifestyle Factors Linked to Altered Biological Aging Markers

Researchers at Yale University have conducted a comprehensive review of 51 clinical studies, published in the journal Nature Medicine, to investigate methods that may influence biological aging. The study, led by Raghav Sehgal, examined over 110 DNA methylation biomarkers, including 16 major epigenetic clocks, to assess changes in biological age before and after various interventions. The findings indicate that certain prescription drugs, such as metformin, semaglutide, and anti-TNF drugs, along with a combination of regular physical activity and healthy diets (Mediterranean, low-fat, or low-carbohydrate), were associated with favorable alterations in molecular markers of aging. Conversely, over-the-counter dietary supplements generally showed no significant effect on these markers. The study also noted that changes in biomarkers were more pronounced in participants with existing health conditions compared to healthy individuals, and newer generations of epigenetic clocks proved more effective in detecting...

GLP-1 Medications Show Promise in Influencing Epigenetic Aging Markers and Extending Lifespan in Mice

GLP-1 Medications Show Promise in Influencing Epigenetic Aging Markers and Extending Lifespan in Mice

Recent research presented at the 2026 Aging Research and Drug Discovery Meeting indicates that GLP-1 medications, such as semaglutide and tirzepatide, are positively influencing epigenetic aging clocks. Novo Nordisk reported that semaglutide improved biological aging measures across multiple organ systems, including the heart and kidneys. Similarly, Eli Lilly presented findings that tirzepatide, found in prescriptions like Mounjaro and Zepbound, affected several epigenetic aging clocks, including organ-specific markers for the heart, kidney, liver, and immune system. A study published in Nature also found that semaglutide extended the lifespan of older female mice by approximately 12 percent, alongside improvements in physical and cognitive function. These independent observations suggest that GLP-1-based therapies may impact biological aging through various molecular pathways, extending these molecular observations to actual lifespan and demonstrating improvements in several hallmarks of aging.

Super Age Games Tests Longevity Markers in Fitness Competition

Super Age Games Tests Longevity Markers in Fitness Competition

Super Age Games Tests Longevity Markers in Fitness Competition

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Ozempic Manufacturer Novo Nordisk Faces Lawsuits Over Alleged Vision Loss Side Effect

Ozempic Manufacturer Novo Nordisk Faces Lawsuits Over Alleged Vision Loss Side Effect

Novo Nordisk, the manufacturer of the GLP-1 medication Ozempic, is facing over 200 lawsuits in the U.S. from individuals claiming the drug caused partial blindness. One such plaintiff, Jay Vandegriff, was prescribed Ozempic in 2023 for type 2 diabetes and experienced a sudden loss of vision on Christmas Day 2024, leading to a diagnosis of non-arteritic anterior ischemic optic neuropathy (NAION). NAION is an optic nerve stroke caused by reduced blood flow, resulting in sudden and often irreversible vision loss. Vandegriff's legal team, Weitz & Luxenberg, states that the risk of NAION was not listed on the U.S. label for Ozempic when he was taking it. The U.S. Food and Drug Administration (FDA) recently announced that GLP-1 medicines must now carry a warning about a potential increased risk of NAION, months after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a similar safety update.

FDA Revises Testosterone Labeling Amidst New Safety Evidence, Emphasizing Diagnostic Scrutiny

FDA Revises Testosterone Labeling Amidst New Safety Evidence, Emphasizing Diagnostic Scrutiny

The U.S. Food and Drug Administration (FDA) has revised its labeling for testosterone products, incorporating newer safety evidence and requesting further revisions by 2026. These changes underscore that testosterone replacement therapy (TRT) is not intended as a general anti-aging treatment. Instead, the FDA's updated guidelines emphasize the necessity of a confirmed deficiency diagnosis and ongoing monitoring for patients considering TRT. Clinicians must now pay closer attention to potential side effects such as blood pressure fluctuations, changes in blood cell counts, and prostate health considerations. The revisions also highlight that TRT can suppress sperm production, advising men with current or future reproductive plans to consult a reproductive specialist. The FDA's stance reinforces that a comprehensive diagnostic process, including appropriate blood tests and clinical assessment, is crucial before initiating TRT, moving away from its use for non-specific symptoms without clear medical indicatio...

BioAI App Offers Personalized Wellness-Age Estimates and Lifestyle Action Plans

BioAI App Offers Personalized Wellness-Age Estimates and Lifestyle Action Plans

BioAI App Offers Personalized Wellness-Age Estimates and Lifestyle Action Plans

University of Pittsburgh Researchers Discover Widespread Drug-Impacting Genetic Variants in All of Us Cohort

University of Pittsburgh Researchers Discover Widespread Drug-Impacting Genetic Variants in All of Us Cohort

A study led by researchers at the University of Pittsburgh, utilizing data from the National Institutes of Health’s All of Us Research Program, has revealed that every individual in a diverse sample of nearly 100,000 participants carries at least one genetic variant affecting how their body processes medications. The study, published in Science Translational Medicine, found that participants had a median of nine such variants. Furthermore, over 24% of these individuals had been prescribed a medication known to interact with a variant they carried. The research team evaluated the frequency of 16 genetic variants known to influence the effectiveness or toxicity of various medications. This discovery highlights the potential for pharmacogenomics (PGx) to improve individualized prescribing and reduce adverse drug effects. The All of Us Research Program, a large-scale initiative, aims to gather health data from one million people across the U.S. to understand how lifestyle, environment, and genes impact health ...

IHMC Researchers Investigate Exercise and Nitrate Supplementation to Combat Aging and Improve Healthspan

IHMC Researchers Investigate Exercise and Nitrate Supplementation to Combat Aging and Improve Healthspan

Researchers at the Institute for Human & Machine Cognition (IHMC) are conducting a new NIH-funded study, BOOST-X, to investigate whether adding a nitrate supplement to endurance and resistance training can further reduce all-cause mortality risk and reverse hallmarks of aging in adults over 59. This study builds on their ongoing five-year clinical trial, M³AX, which aims to demonstrate exercise's ability to improve healthspan and quality of life. Dr. Marcas Bamman, Senior Research Scientist at IHMC and Director of Healthspan, Resilience and Performance Research, leads the BOOST-X trial. The study will be a randomized, double-blind, placebo-controlled trial, with participants receiving either a nitrate supplement (beetroot juice) or a placebo. The goal is to enhance vascular and cardiorespiratory function, improve mitochondrial function, reduce inflammation, and lower oxidative stress, particularly for older adults who may have reduced nitric oxide synthesis and stiff arteries. The multi-site trial, involvi...

BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium

BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium

BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium

US to fund new research into psychedelic drug ibogaine for veterans with PTSD

US to fund new research into psychedelic drug ibogaine for veterans with PTSD

Nov 12 (Reuters) - The US government will spend up to $4.9 million to prepare for clinical trials of psychedelic drug ibogaine as a possible treatment for veterans with post-traumatic stress disorder (PTSD), Health Secretary Robert F. Kennedy Jr. said on Thursday.

Cleveland Clinic Researchers Advance Dual-Target siRNA Therapy for Mixed Hyperlipidemia

Cleveland Clinic Researchers Advance Dual-Target siRNA Therapy for Mixed Hyperlipidemia

Cleveland Clinic researchers have presented first-in-human findings on a novel dual-function small interfering RNA (siRNA) therapeutic, ARO-DIMER-PA, designed to simultaneously lower both LDL cholesterol (LDL-C) and triglycerides. This development addresses mixed hyperlipidemia, a common lipid disorder that typically requires separate treatments for its components. The phase 1/2a trial, presented at the American Heart Association’s 2026 Scientific Sessions, demonstrated that a single dose of ARO-DIMER-PA sustained suppression of both PCSK9 and APOC3 proteins, leading to substantial reductions in LDL-C (26% to 65%) and triglycerides (56% to 78%). The drug was generally well tolerated, with injection-site erythema being the most common adverse event. This bifunctional therapy represents a significant step forward, as existing siRNA drugs typically target only one of these proteins.